Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency

被引:45
作者
Bell, IM
Gallicchio, SN
Abrams, M
Beshore, DC
Buser, CA
Culberson, JC
Davide, J
Ellis-Hutchings, M
Fernandes, C
Gibbs, JB
Graham, SL
Hartman, GD
Heimbrook, DC
Homnick, CF
Huff, JR
Kassahun, K
Koblan, KS
Kohl, NE
Lobell, RB
Lynch, JJ
Miller, PA
Omer, CA
Rodrigues, AD
Walsh, ES
Williams, TM
机构
[1] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA
[3] Merck Res Labs, Dept Mol Syst, W Point, PA 19486 USA
[4] Merck Res Labs, Dept Drug Metab, W Point, PA 19486 USA
[5] Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA
关键词
D O I
10.1021/jm010156p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis, structure-activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-amino-pyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model.
引用
收藏
页码:2933 / 2949
页数:17
相关论文
共 50 条
[11]   P21RAS IS MODIFIED BY A FARNESYL ISOPRENOID [J].
CASEY, PJ ;
SOLSKI, PA ;
DER, CJ ;
BUSS, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8323-8327
[12]  
CLAREMON DA, 1993, PERSPECTIVES MED CHE, P389
[13]  
Dabrah TT, 1997, J ANTIBIOT, V50, P1
[14]  
End D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P270
[15]  
FERRACCIOLI R, 1991, FARMACO, V46, P1517
[16]   [H-3]Dofetilide binding: Biological models that manifest solely the high or the law affinity binding site [J].
Fiset, C ;
Feng, ZP ;
Wang, L ;
Sheldon, RS ;
Duff, HJ .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1996, 28 (05) :1085-1096
[17]   BIOACTIVE CONFORMATION OF LUTEINIZING-HORMONE-RELEASING HORMONE - EVIDENCE FROM A CONFORMATIONALLY CONSTRAINED ANALOG [J].
FREIDINGER, RM ;
VEBER, DF ;
PERLOW, DS ;
BROOKS, JR ;
SAPERSTEIN, R .
SCIENCE, 1980, 210 (4470) :656-658
[18]   PROTECTED LACTAM-BRIDGED DIPEPTIDES FOR USE AS CONFORMATIONAL CONSTRAINTS IN PEPTIDES [J].
FREIDINGER, RM ;
PERLOW, DS ;
VEBER, DF .
JOURNAL OF ORGANIC CHEMISTRY, 1982, 47 (01) :104-109
[19]  
Fukazawa H, 1996, INT J CANCER, V67, P876, DOI 10.1002/(SICI)1097-0215(19960917)67:6<876::AID-IJC19>3.0.CO
[20]  
2-#